Chandra Choudhury

About

Dr Choudhury obtained her PhD in Molecular Pharmacology from the University of Queensland in 2022. In her PhD, she researched the regulation of mitochondrial function in metabolic diseases and published in the fields of pharmacology, biochemistry, oncology, and translational science. Dr Choudhury joined the Cancer Neuroscience lab at QIMR Berghofer in 2023 as a post-doctoral researcher and is currently investigating the mechanisms required to target quiescence glioblastoma stem cells. She has been teaching at the University of Queensland since 2018 and has co-supervised 3 Honours students and 1 current PhD student.

Employment

• QIMR Berghofer Medical Research Institute Research Officer
  2023 - Present

Education

• The University of Queensland Press Doctor of Philosophy
  2019 - 2022
• The University of Queensland Bachelor of Biomedical Science (Honours)
  2015 - 2018

Projects & Funding

Projects & funding information is unavailable.

Publications (11)

• Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma
  Nature Communications 2025 DOI: 10.1038/s41467-025-65888-5
  +Save
• Sequential transcriptional programs underpin activation of hippocampal stem cells.
  Science Advances 2025 DOI: 10.1126/sciadv.adu4523
  +Save
• Arylamine N-acetyltransferase 1 expression predicts glucose dependence and mitochondrial bioenergetics in cancer cells
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2025 DOI: 10.1016/j.bbamcr.2025.119929
  +Save
• Shared molecular regulation of quiescence in neural and glioma stem cells reveals therapeutic vulnerabilities
  2025 DOI: 10.1101/2025.01.22.634421
  +Save
• Tools to study neural and glioma stem cell quiescence
  Trends in Neurosciences 2024 DOI: 10.1016/j.tins.2024.07.004
  +Save
• Small Molecule Inhibitors of Arylamine N-Acetyltransferase 1 Attenuate Cellular Respiration
  ACS Pharmacology & Translational Science 2024 DOI: 10.1021/acsptsci.4c00282
  +Save
• The Arylamine N-Acetyltransferases as Therapeutic Targets in Metabolic Diseases Associated with Mitochondrial Dysfunction
  Pharmacological Reviews 2024 DOI: 10.1124/pharmrev.123.000835
  +Save
• Contrasting Effects of Temperature on Human Arylamine N-Acetyltransferase and Acetyl Coenzyme A Hydrolase Activities
  Biochemistry 2023 DOI: 10.1021/acs.biochem.3c00113
  +Save
• Human arylamine N-acetyltransferase 1 expression alters mitochondrial function in metabolic diseases
  2023 DOI: 10.14264/05865cf
  +Save
• Polymorphism in the human arylamine N-acetyltransferase 1 gene 3′-untranslated region determines polyadenylation signal usage
  Biochemical Pharmacology 2022 DOI: 10.1016/j.bcp.2022.115020
  +Save